Cover Image
市場調查報告書

全球蛋白質療法市場

Global Protein Therapeutics Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 235810
出版日期 內容資訊 英文 165 Pages
訂單完成後即時交付
價格
Back to Top
全球蛋白質療法市場 Global Protein Therapeutics Market Outlook 2020
出版日期: 2015年09月01日 內容資訊: 英文 165 Pages
簡介

蛋白質療法,成為對癌症到代謝性疾病廣泛疾病的最有效的治療之一。預計這個市場將來有大幅成長的可能性,到2020年末達2,080億美元的規模。

本報告提供蛋白質療法的全球市場相關分析、市場整體結構和趨勢預測、主要的治療方法、治療藥概要與市場趨勢的預測、最新的藥物開發趨勢、市場新趨勢、主要企業簡介等調查評估,並將其結果為您概述為以下內容。

第1章 分析師的見解

第2章 分析方法

第3章 全球蛋白質療法市場

  • 蛋白質療法市場與醫藥品市場
  • 現在、未來市場分析
    • 市場分類
    • 市場動態
      • 成長推動因素
      • 抑制因素
      • 課題
      • 機會

第4章 產業的實際成果

  • 單株抗體(mAbs)
    • 科學性考察
    • 現在、未來市場分析
    • 各用途分析
    • 主要市場地區
    • 主要企業與藥物
    • 近幾年的發展
  • 促血紅細胞生長素(EPO)
    • 科學性考察
    • 現在、未來市場分析
    • 各用途分析
    • 主要市場地區
    • 主要企業與藥物
    • 近幾年的發展
  • 胰島素
    • 科學性考察
    • 現在、未來市場分析
    • 各用途分析
    • 主要市場地區
    • 主要企業與藥物
    • 近幾年的發展
  • 干擾素(IFN)
    • 科學性考察
    • 現在、未來市場分析
    • 各用途分析
    • 主要市場地區
    • 主要企業與藥物
    • 近幾年的發展
  • 人體生長荷爾蒙(HGH)
    • 科學性考察
    • 現在、未來市場分析
    • 主要市場地區
    • 主要企業與藥物
    • 近幾年的發展
  • 凝血因子
    • 科學性考察
    • 現在、未來市場分析
    • 各因素分析
    • 主要市場地區
    • 主要企業與藥物
    • 近幾年的發展
  • 濾泡刺激素(FSH)
    • 科學性考察
    • 現在、未來市場分析
    • 主要企業與藥物
    • 近幾年的發展
  • 顆粒細胞增生因子(G-CSF)
    • 科學性考察
    • 現在、未來市場分析
    • 主要市場地區
    • 主要企業與藥物
    • 近幾年的發展

第5章 處於臨床實驗的最後階段的藥物分析

第6章 市場新趨勢

  • 正式化:為了開發新的治療方法的企業間策略性活動
  • 有效到達方法:擴大治療藥的有效範圍
  • 高額投資多發性硬化症及癌症治療的企業
  • 新的生物醫藥品,著重「生技改良藥」的開發

第7章 主要企業

  • Johnson & Johnson
  • Biogen Idec Inc.
  • Eli Lilly & Company
  • Sanofi-Aventis
  • Merck Serono S.A.
  • Roche Group
  • Amgen Inc.
  • Pfizer
  • Abbott Laboratories
  • Novo Nordisk

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Once a rarely used subset of medical treatments, protein therapies have now found application in a large number of medical conditions. Since the introduction of the first recombinant protein therapeutic, the human insulin, the protein therapeutics market has revolutionized tremendously. Due to its increased usage, the market holds huge potential for future growth and it is estimated that by the end of 2020, it may reach the mark of US$ 208 Billion. Furthermore, the launch of new products is also likely to propel the market growth.

According to our new research report, “Global Protein Therapeutics Market Outlook 2020”, a large number of existing and new market players are rigorously involved in developing monoclonal antibodies (mAbs). The mAbs segment accounts for the largest share in the current protein therapeutic products. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments, which includes insulin, EPO, interferon, G-CSF, human growth hormone , blood clotting factors and FSH.

The report takes into account all the important aspects of the global protein therapeutics market, and projects the market during the period 2013-2020. Some of the key aspects included in the report are the market share analysis of key players and the segmental analysis. The report also provides in depth analysis of various applications of the above mentioned protein therapeutics. The current as well as the future market prospects of the applications of major protein therapeutics is also provided in the report.

Through in-depth and careful analysis of the worldwide developments, we have observed that the US continues to hold a dominant position in the global protein therapeutics market, as the country provides a major proportion of the products' sales. However, our team of researchers has come up with an analysis that the future landscape looks promising, with respect to major contribution from emerging economies, which can be attributed to increasing awareness among people and an increased healthcare expenditure owing to the increase in the disposable income.

The report also covers an advanced phase drug analysis. This chapter lists all the protein therapeutics of the major players, which are in the third phase of the clinical trial. This analysis will help the client in understanding the potential market for the future. It also helps understand the major segments, indications and players in Protein Therapeutics that will continue to rule the market.

The report also states market forces that would govern the market, the drivers for the market, the challenges encountered by the market players, and the opportunities that the new and existing market players could grab, thereby resulting in the growth of the market. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance.

The report provides insight about the lucrativeness of the industry through Porter's Five Forces Analysis. This analysis will help the industry players to understand the level of competition within an industry, and would assist in business strategy development.

At the end, the key players of the market have been enlisted. A brief business overview of every player has been provided along with its product portfolio. This is followed by the recent developments of the player that may impact the market in the future. Overall, the report will prove to be a complete source of knowledge, and analysis for clients and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Global Protein Therapeutics Market

  • 3.1. Protein Therapeutics Market vs Pharmaceutical Market
  • 3.2. Current and Future Market Analysis to 2020
    • 3.2.1. Market Segmentation
    • 3.2.2. Market Dynamics
      • 3.2.2.1. Drivers
        • 3.2.2.1.1. Increasing Healthcare Expenditure in the Emerging Markets
        • 3.2.2.1.2. Government Initiatives to Improve the Healthcare Services
        • 3.2.2.1.3. Rising Prevalence of Chronic Diseases
        • 3.2.2.1.4. Growing Geriatric Population
      • 3.2.2.2. Challenges
        • 3.2.2.2.1. High Cost of Production and Treatment
        • 3.2.2.2.2. Competition from Biosimilars
        • 3.2.2.2.3. Patent Expiry of Blockbuster Drugs
      • 3.2.2.3. Opportunities
        • 3.2.2.3.1. Potential for Bispecific Monoclonal Antibodies
        • 3.2.2.3.2. Unmet Medical Needs in the Developing Countries

4. Industry Performance

  • 4.1. Monoclonal Antibodies (mAbs)
    • 4.1.1. Scientific Insight
    • 4.1.2. Current and Future Market Analysis to 2020
    • 4.1.3. By Application
    • 4.1.4. Key Geographical Markets
    • 4.1.5. Key Players and Drugs
    • 4.1.6. Recent Developments
  • 4.2. Erythropoietin (EPO)
    • 4.2.1. Scientific Insight
    • 4.2.2. Current and Future Market Analysis to 2020
    • 4.2.3. By Application
    • 4.2.4. Key Geographical Markets
    • 4.2.5. Key Players and Drugs
    • 4.2.6. Recent Developments
  • 4.3. Insulin
    • 4.3.1. Scientific Insight
    • 4.3.2. Current and Future Market Analysis to 2020
    • 4.3.3. By Application
    • 4.3.4. Key Geographical Markets
    • 4.3.5. Key Players and Drugs
    • 4.3.6. Recent Developments
  • 4.4. Interferon (IFN)
    • 4.4.1. Scientific Insight
    • 4.4.2. Current and Future Market Analysis to 2020
    • 4.4.3. By Application
    • 4.4.4. Key Geographical Markets
    • 4.4.5. Key Players and Drugs
    • 4.4.6. Recent Developments
  • 4.5. Human Growth Hormone (HGH)
    • 4.5.1. Scientific Insight
    • 4.5.2. Current and Future Market Analysis to 2020
    • 4.5.3. Key Geographical Markets
    • 4.5.4. Key Players and Drugs
    • 4.5.5. Recent Developments
  • 4.6. Blood Clotting Factor
    • 4.6.1. Scientific Insight
    • 4.6.2. Current and Future Market Analysis to 2020
    • 4.6.3. By Factor Type
    • 4.6.4. Key Geographical Markets
    • 4.6.5. Key Players and Drugs
    • 4.6.6. Recent Developments
  • 4.7. Follicle Stimulating Hormone (FSH)
    • 4.7.1. Scientific Insight
    • 4.7.2. Current and Future Market Analysis to 2020
    • 4.7.3. Key Players and Drugs
    • 4.7.4. Recent Developments
  • 4.8. Granulocyte Colony Stimulating Factor (G-CSF)
    • 4.8.1. Scientific Insight
    • 4.8.2. Current and Future Market Analysis to 2020
    • 4.8.3. Key Geographical Markets
    • 4.8.4. Key Players and Drugs
    • 4.8.5. Recent Developments

5. Advanced Phase Drugs Analysis

6. Emerging Market Trends

  • 6.1. Gaining Momentum: Strategic Activities among Players to Develop Novel Treatments
  • 6.2. Effective Delivery Methods: Improving the Reach of Therapies
  • 6.3. Players Investing Heavily in Multiple Sclerosis and Cancer Therapeutics
  • 6.4. Increasing Focus on Development of Biobetters

7. Porters Five Forces Analysis

8. Key Players

  • 8.1. Johnson & Johnson
  • 8.2. Biogen Idec Inc.
  • 8.3. Eli Lilly & Company
  • 8.4. Sanofi-Aventis
  • 8.5. Merck Serono S.A.
  • 8.6. Roche Group
  • 8.7. Amgen Inc.
  • 8.8. Pfizer
  • 8.9. Abbott Laboratories
  • 8.10. Novo Nordisk

List of Figures:

  • Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2014
  • Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2013-2020
  • Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2014
  • Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2020
  • Figure 4-1: Global - Monoclonal Antibodies Market (Billion US$), 2013-2020
  • Figure 4-2: Global - Monoclonal Antibodies Market by Application (%), 2014
  • Figure 4-3: Global - Monoclonal Antibodies Application in Cancer Treatment (Billion US$), 2013-2020
  • Figure 4-4: Global - Monoclonal Antibodies Application in Rheumatoid Arthritis Treatment (Billion US$), 2013-2020
  • Figure 4-5: Global - Monoclonal Antibodies Application in Other Chronic Diseases Treatment (Billion US$), 2013-2020
  • Figure 4-6: US - Monoclonal Antibodies Market (Billion US$), 2013-2020
  • Figure 4-7: Europe - Monoclonal Antibodies Market (Billion US$), 2013-2020
  • Figure 4-8: Japan - Monoclonal Antibodies Market (Billion US$), 2013-2020
  • Figure 4-9: Global - Monoclonal Antibody Market by Key Players (%) (2014)
  • Figure 4-10: Global - Erythropoietin Market (Billion US$), 2012-2018
  • Figure 4-11: Global - Erythropoietin Market by Segment (%) (2014)
  • Figure 4-12: Global - Number of Patients on Dialysis (Million), 2014 & 2020
  • Figure 4-13: Global - Breakup of Patients on Dialysis by Region (%), 2014
  • Figure 4-14: Global - Number of New Cancer Cases (Million), 2012 & 2020
  • Figure 4-15: Global - Breakup of New Cancer Cases by Region (%), 2020
  • Figure 4-16: US - Erythropoietin Market (Billion US$), 2013-2020
  • Figure 4-17: Europe - Erythropoietin Market (Billion US$), 2013-2020
  • Figure 4-18: Global - Erythropoietin Market by Key Player (%), (2014)
  • Figure 4-19: Global - Insulin Market (Billion US$), 2013-2020
  • Figure 4-20: Global - Number of Diabetic Patients (Million), 2013 & 2035
  • Figure 4-21: US - Insulin Market (Billion US$), 2013-2020
  • Figure 4-22: Europe - Insulin Market (Billion US$), 2013-2020
  • Figure 4-23: Asia - Insulin Market (Billion US$), 2013-2020
  • Figure 4-24: Global - Insulin Market by Key Players (%) (2014)
  • Figure 4-25: Global - Insulin Market by Products (%)(2014)
  • Figure 4-26: Global - Interferon Market (Billion US$), 2013-2020
  • Figure 4-27: Global - Interferon Market by Segment (%) (2014)
  • Figure 4-28: Global - Interferon Alpha Market (Billion US$), 2012-2014
  • Figure 4-29: Global - Interferon Beta Market (Billion US$), 2012-2014
  • Figure 4-30: US - Interferon Market (Billion US$), 2013-2020
  • Figure 4-31: Europe - Interferon Market (Billion US$), 2013-2020
  • Figure 4-32: Global - Interferon Market by Key Player (%) (2014)
  • Figure 4-33: Global - Human Growth Hormone Market (Billion US$), 2013-2020
  • Figure 4-34: US - Human Growth Hormone Market (Billion US$), 2013-2020
  • Figure 4-35: Europe - Human Growth Hormone Market (Billion US$), 2013-2020
  • Figure 4-36: Global - Human Growth Hormone Market by Key Players (%) (2014)
  • Figure 4-37: Global - Blood Clotting Factor Market (Billion US$), 2013-2020
  • Figure 4-38: Global - Blood Clotting Factor Market by Segment (%) (2014)
  • Figure 4-39: Global - Blood Clotting Recombinant Factor VIII Market (Billion US$), 2013-2020
  • Figure 4-40: Global - Recombinant Blood Clotting Factor VII Market (Billion US$), 2013-2020
  • Figure 4-41: Global - Recombinant Blood Clotting Factor Market IX (Billion US$), 2013-2020
  • Figure 4-42: US - Blood Clotting Factor Market (Billion US$), 2013-2020
  • Figure 4-43: Europe - Blood Clotting Factor Market (Billion US$), 2013-2020
  • Figure 4-44: Global - Blood Clotting Factor Market by Key Players (%) (2014)
  • Figure 4-45: Global - Follicle Stimulating Hormone Market (Billion US$), 2013-2020
  • Figure 4-46: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2013-2020
  • Figure 4-47: US - Granulocyte Colony-Stimulating Factor Market (Billion US$), 2013-2020
  • Figure 4-48: Europe - Granulocyte Colony-Stimulating Factor Market (Billion US$), 2013-2020
  • Figure 7-1: Porters Five Forces Analysis

List of Tables:

  • Table 3-1: US & Europe - Major Drugs Patent Expiry in Protein Therapeutics Market
  • Table 4-1: Global - Key Players and Drugs in Monoclonal Antibody Market (Billion US$), 2012-2014
  • Table 4-2: Global - Key Players and Drugs in Erythropoietin Alfa Market (Billion US$), 2012-2014
  • Table 4-3: Global - Key Players and Drugs in Erythropoietin Beta Market (Billion US$), 2012-2014
  • Table 4-4: Global - Key Players and Drugs in Darbepoetin Market (Billion US$), 2012-2014
  • Table 4-5: US - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035f
  • Table 4-6: Europe - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035
  • Table 4-7: China - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035f
  • Table 4-8: Global - Key Players and Drugs in Interferon Alpha Market (Billion US$), 2012-2014
  • Table 4-9: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2012-2014
  • Table 4-10: Global - Key Players and Drugs in Human Growth Hormone Market (Billion US$), 2012-2014
  • Table 4-11: Global - Key Players and Drugs in Blood Clotting Factor Market (Billion US$), 2012-2014
  • Table 4-12: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Billion US$), 2012-2014
  • Table 4-13: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Billion US$), 2012-2014
  • Table 5-1: Advanced Phase Protein Therapeutics
  • Table 8-1: Johnson & Johnson - Key Products in Protein Therapeutics
  • Table 8-2: Biogen - Key Products in Protein Therapeutics
  • Table 8-3: Eli Lilly - Key Products in Protein Therapeutics
  • Table 8-4: Sanofi-Aventis - Key Products in Protein Therapeutics
  • Table 8-5: Merck Serono - Key Products in Protein Therapeutics
  • Table 8-6: Roche - Key Products in Protein Therapeutics
  • Table 8-7: Amgen Inc. - Key Products in Protein Therapeutics
  • Table 8-8: Pfizer Inc. - Key Products in Protein Therapeutics
  • Table 8-9: Abbott Laboratories - Key Products in Protein Therapeutics
  • Table 8-10: Novo Nordisk - Key Products in Protein Therapeutics
Back to Top